Prothena (NASDAQ: PRTA) — Perfil da empresa, notícias e dados financeiros
Prothena (NASDAQ:PRTA) is a biotechnology company focused on discovering and developing novel therapies in the field of neuroscience. Its mission
Prothena
Prothena (NASDAQ:PRTA) is a biotechnology company focused on discovering and developing novel therapies in the field of neuroscience. Its mission centers on leveraging deep scientific insights to advance the treatment of diseases characterized by misfolded proteins, such as amyloidosis and Parkinson's disease. Prothena's pipeline showcases a range of therapies aimed at addressing some of the most challenging neurodegenerative diseases, with projects spanning from early discovery to late-stage clinical trials. The objectives of Prothena are to deliver innovative treatments that can significantly improve patients' lives while advancing the understanding of the underlying biology of these complex diseases. Through a commitment to science and innovation, Prothena aims to lead the way in developing next-generation therapies that target the root causes of neurodegenerative diseases, offering hope to patients and families affected by these conditions.
Resumo
Operações
Produtos e/ou serviços de Prothena
- Birtamimab, a treatment for AL amyloidosis aiming to improve organ function by targeting amyloid deposits.
- PRX004, a novel antibody for ATTR amyloidosis, designed to deplete misfolded proteins and halt disease progression.
- PRX012, an antibody for Alzheimer's disease, focusing on clearing beta-amyloid plaques to slow cognitive decline.
- Neuroscience programs targeting Parkinson’s disease, including antibodies to clear alpha-synuclein aggregates.
- Collaboration with Roche on potential treatments for neurodegenerative diseases, leveraging their global reach and development capabilities.
- Cardiovascular disease research, exploring novel targets for heart-related conditions, aiming to address unmet medical needs.
equipe executiva do Prothena
- Gene G. KinneyPresident, CEO & Director
- Tran B. NguyenChief Financial Officer
- Brandon S. SmithChief Operating Officer
- Wagner M. ZagoChief Scientific Officer
- Karin L. WalkerChief Accounting Officer & Controller
- Mark C. JohnsonVice President of Investor Relations
- Michael J. IsaacsGeneral Counsel & Corporate Secretary
- Phillip DolanSr. Director & Head of Exploratory Research
- Annie Evans KingstonChief Strategy Officer
Principais indicadores financeiros
Resultados divulgados pela Prothena , em USD.
- Cap. de mercado
- 467,2 mi
- Receita (TTM)
- 54,5 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.8
- Dividend yield
- —
- Margem de lucro
- -80.7%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 9,7 mi | -184,6 mi | -244,1 mi | |
| 135,2 mi | -154,6 mi | -122,3 mi | |
| 91,4 mi | -191 mi | -147 mi | |
| 53,9 mi | -131,6 mi | -116,9 mi |